Effects of tetrahedral DNA nanostructures on the treatment of osteoporosis

Abstract

Osteoporosis (OP) is a common disease characterized by bone loss and bone tissue microstructure degradation. Drug treatment is a common clinical treatment that aims to increase bone mass and bone density. Tetrahedral DNA nanostructures (TDNs) are three-dimensional tetrahedral frames formed by folding four single-stranded DNA molecules, which have good biological safety and can promote bone regeneration. In this study, a mouse model of OP was established by ovariectomy (OVX) and TDN was injected into the tail vein for 8 weeks. We found that ovariectomized mice could simulate some physiological changes in OP. After treatment with TDNs, some of this destruction in mice was significantly improved, including an increase in the bone volume fraction (BV/TV) and bone trabecular number (Tb. N), decrease in bone separation (Tb. SP), reduction in the damage to the mouse cartilage layer, reduction in osteoclast lacunae in bone trabecula, and reduction in the damage to the bone dense part. We also found that the expression of ALP, β-Catenin, Runx2, Osterix, and bone morphogenetic protein (BMP)2 significantly decreased in OVX mice but increased after TDN treatment. Therefore, this study suggests that TDNs may regulate the Wnt/β-Catenin and BMP signalling pathways to improve the levels of some specific markers of osteogenic differentiation, such as Runx2, ALP, and Osterix, to promote osteogenesis, thus showing a therapeutic effect on OP mice.

References

[1] Das S, Crockett J. Osteoporosis – a current view of pharmacological prevention and treatment. Drug des Devel Ther. 2013;7:435-448.

[2] Cheung A, Papaioannou A, Morin S. Postmenopausal osteoporosis. N Engl J Med. 2016;374(21):2096.

[3] Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ. Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res. 2014;29(3):581-589.

[4] Raisz L. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318-3325.

[5] Kim B, Koh J. Coupling factors involved in preserving bone balance. Cell Mol Life Sci. 2019;76(7):1243-1253.

[6] Su Y, Wang W, Liu F, et al. Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis. Ann Palliat Med. 2022;11(10):3203-3212.

[7] Yuan Q, Huang J, Xian C, Wu J. Amino acid- and growth factor-based multifunctional Nanocapsules for the modulation of the local microenvironment in tissue engineering. ACS Appl Mater Interfaces. 2021;13(2):2165-2178.

[8] Seeto A, Tadrous M, Gebre AK, et al. Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone. 2022;167:116610.

[9] Lim S. Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk. Womens Health (Lond Engl). 2022;18:17455057221125577.

[10] Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol. 2002;55(9):693-698.

[11] Dou Y, Cui W, Yang X, Lin Y, Ma X, Cai X. Applications of tetrahedral DNA nanostructures in wound repair and tissue regeneration. Burns Trauma. 2022;10:tkac006.

[12] Ma W, Zhan Y, Zhang Y, Mao C, Xie X, Lin Y. The biological applications of DNA nanomaterials: current challenges and future directions. Signal Transduct Target Ther. 2021;6(1):351.

[13] Zhang T, Tian T, Lin Y. Functionalizing framework nucleic acid-based nanostructures for biomedical application. Adv Mater. 2021;34(46):e2107820.

[14] Chen T, Xiao D, Li Y, et al. Tetrahedral framework nucleic acids regulate osteogenic differentiation potential of osteoporotic adipose-derived stem cells. Chin Chem Lett. 2022;33(5):2517-2521.

[15] Zhang T, Tian T, Zhou R, et al. Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat Protoc. 2020;15(8):2728-2757.

[16] Sirong S, Yang C, Taoran T, et al. Effects of tetrahedral framework nucleic acid/wogonin complexes on osteoarthritis. Bone Res. 2020;8:6.

[17] Shao X, Lin SY, Peng Q, et al. Effect of tetrahedral DNA nanostructures on osteogenic differentiation of mesenchymal stem cells via activation of the Wnt/β-catenin signaling pathway. Nanomedicine. 2017;13(5):1809-1819.

[18] Inada M, Matsumoto C, Miyaura C. Animal models for bone and joint disease. Ovariectomized and orchidectomized animals. Clin Calcium. 2011;21(2):164-170.

[19] Appelman-Dijkstra N, Papapoulos S. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat Rev Endocrinol. 2018;14(10):605-623.

[20] Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature. 2000;407(6803):530-535.

[21] Davidson G, Wu W, Shen J, et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature. 2005;438(7069):867-872.

[22] Pittenger M, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.

[23] Chamberlain J, Schwarze U, Wang PR, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science. 2004;303(5661):1198-1201.

[24] Kim J, Liu X, Wang J, et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis. 2013;5(1):13-31.

[25] Monroe D, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492(1):1-18.

[26] Hoeppner L, Secreto F, Westendorf J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13(4):485-496.

[27] Wen Q, Jing J, Han X, et al. Runx2 regulates mouse tooth root development via activation of WNT inhibitor NOTUM. J Bone Min Res. 2020;35(11):2252-2264.

[28] Pérez-Campo F, Santurtún A, García-Ibarbia C, et al. Osterix and RUNX2 are transcriptional regulators of Sclerostin in human bone. Calcif Tissue Int. 2016;99(3):302-309.

[29] Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 2010;339(1):189-195.

[30] Matzelle M, Shaw AT, Baum R, et al. Inflammation in arthritis induces expression of BMP3, an inhibitor of bone formation. Scand J Rheumatol. 2016;45(5):379-383.

[31] McLarren K, Lo R, Grbavec D, Thirunavukkarasu K, Karsenty G, Stifani S. The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1. J Biol Chem. 2000;275(1):530-538.

[32] Mbalaviele G, Sheikh S, Stains JP, et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005;94(2):403-418.

[33] Zhang R, Oyajobi BO, Harris SE, et al. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone. 2013;52(1):145-156.

[34] Kook S, Heo J, Lee J. Crucial roles of canonical Runx2-dependent pathway on Wnt1-induced osteoblastic differentiation of human periodontal ligament fibroblasts. Mol Cell Biochem. 2015;402:213-223.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.